Acute promyelocytic leukemia medical Interventions

Acute promyelocytic leukemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Acute promyelocytic leukemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Other Imaging Studies
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary PreventionSurgery
Secondary PreventionSurgery
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Acute promyelocytic leukemia medical Interventions On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Acute promyelocytic leukemia medical Interventions All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Acute promyelocytic leukemia medical Interventions
CDC on Acute promyelocytic leukemia medical Interventions
Acute promyelocytic leukemia medical Interventions in the news
Blogs on Acute promyelocytic leukemia medical Interventions
Directions to Hospitals Treating Acute promyelocytic leukemia
Risk calculators and risk factors for Acute promyelocytic leukemia medical Interventions

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: , Sogand Goudarzi, MD [2]

Overview

The mainstay of treatment for acute promyelocytic leukemia is cytotoxic chemotherapy.combination of all-trans retinoic acid and arsenic trioxide is usually reserved for patients with either relapse, resistant to further treatment.

Indications

• The mainstay of treatment for acute promyelocytic leukemia is cytotoxic chemotherapy.combination of all-trans retinoic acid and arsenic trioxide is usually reserved for patients with either relapse, resistant to further treatment..